Inactief instrument

Andere talen Soligenix Inc OTC Bulletin Board

Aandelen

US8342232084

slotkoers OTC Bulletin Board Andere beurzen
- ^USD	-

16/05	Soligenix, Inc. Kondigt positieve klinische resultaten aan van de compatibiliteitsstudie van HyBryte in de behandeling van cutaan T-cellymfoom	CI
10/05	Soligenix, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting	20/05
Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma	16/05
Soligenix Announces Recent Accomplishments and First Quarter 2024 Financial Results	13/05
Soligenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results	10/05
Soligenix to Present at Upcoming Conferences	06/05
Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa	25/04
Soligenix Announces Pricing of $4.75 Million Public Offering	18/04
Sector Update: Health Care Stocks Softer Late Afternoon	15/04
Sector Update: Health Care Stocks Gain Monday Afternoon	15/04
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation	15/04
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA	15/04
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection	15/04
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection	11/04
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency	03/04
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency	03/04
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results	15/03
Soligenix Announces Formation of Beh et s Disease Medical Advisory Board	09/02
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board	08/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Soligenix Inc OTC Bulletin Board

Aandelen

US8342232084

Andere talen

Filters